# Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
Canonical URL: https://biopharmsignal.com/news/STXS/stereotaxis-to-report-first-quarter-2026-financial-results-on-may-12-2026-3a325fa0
Ticker: STXS
Company: Stereotaxis
Source: Stereotaxis
Published: 2026-04-21 13:01 EST
## Summary

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive...

## Article Body
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.

| What: |  | Stereotaxis first quarter 2026 financial results conference call |
| --- | --- | --- |
| When: |  | Tuesday, May 12, 2026, at 4:30 p.m. ET (1:30 p.m. PT) |
| Dial In Number: |  | To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 6082771. |
| Webcast: |  | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/ . |
| Call Replay: |  | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here . |

About Stereotaxis Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com .

Investor Contacts: David L. Fischel Chairman and Chief Executive Officer

Kimberly Peery Chief Financial Officer

314-678-6100 Investors@Stereotaxis.com
## Recent Company News
- 2026-07-21 13:00 EST — [Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026](https://biopharmsignal.com/news/STXS/stereotaxis-to-report-second-quarter-2026-financial-results-on-august-11-2026-40f8033c) — Source: Stereotaxis
- 2026-07-20 12:31 EST — [University of Szeged Pioneers First Robotic Cardiology Program in Hungary](https://biopharmsignal.com/news/STXS/university-of-szeged-pioneers-first-robotic-cardiology-program-in-hungary-f69bf77d) — Source: Stereotaxis
- 2026-07-09 12:08 EST — [Stereotaxis Completes Acquisition of Robocath](https://biopharmsignal.com/news/STXS/stereotaxis-completes-acquisition-of-robocath-cf0c62e9) — Source: Stereotaxis
- 2026-05-12 20:06 EST — [Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates](https://biopharmsignal.com/news/STXS/stereotaxis-reports-2026-first-quarter-financial-results-business-updates-369195bc) — Source: Stereotaxis
- 2026-04-22 11:58 EST — [Stereotaxis Announces First MAGiC Procedures in the United States](https://biopharmsignal.com/news/STXS/stereotaxis-announces-first-magic-procedures-in-the-united-states-ae393ae4) — Source: Stereotaxis
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)